esmo 2018: pt2977 for vhl-associated renal cell carcinoma
Published 4 years ago • 21 plays • Length 3:25Download video MP4
Download video MP3
Similar videos
-
3:00
pt2977 for vhl-associated rcc
-
6:09
belzutifan for vhl disease-associated renal cell carcinoma
-
6:10
esmo 2018: dr. george highlights key abstracts in kidney and prostate cancers
-
7:44
asco: a novel therapy for vhl disease-associated renal cell carcinoma
-
7:44
asco: a novel therapy for vhl disease-associated renal cell carcinoma
-
4:17
approach to renal masses among patients with vhl disease
-
25:09
kidney cancer highlights from esmo 2022
-
2:15
mk-6482 shows promise in von hippel-lindau disease-associated renal cell carcinoma
-
3:29
targeting hif-2a in the management of vhl-associated rcc
-
6:22
von hippel lindau disease - case based discussion usmle step 1 pathology
-
3:28
mk-6482 to treat renal cell carcinoma in von hippel-lindau disease patients
-
1:38
kidney cancer research at esmo 2020: toni choueiri, md
-
2:21
phase ii study of the oral hif-2α inhibitor mk-6482 for vhl ccrcc: update
-
2:58
real world effectiveness of pazopanib in patients with intermediate risk renal cell carcinoma
-
4:13
novel hif-2a inhibitor for patients with advanced renal cell carcinoma
-
0:59
updates in kidney cancer at esmo 2022
-
9:08
von hippel--lindau disease
-
5:12
von hippel lindau disease || kidney || renal
-
1:48
dr. jonasch on next steps with mk-6482 in von hippel-lindau disease–associated rcc